Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Dependent Nephrotic Syndrome

Model scores of the 29,894 trials active now.

Model score 16% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase and sponsor type, started 2008–2016) ended terminated 11% of the time (234 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-09-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cellscellremissionrelapsetreating
  Phrases that lowered it: and safetyefficacy andsafety ofvaccinationsingle
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Phase: 3 (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 1 (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 25.0% (raises risk) · Drug's FDA history
• Responsible party: principal investigator (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports marked serious: 95.2% (raises risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Minimum age: 3 (lowers risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Maximum age: 16 (raises risk) · Who can join
• Sponsor's past trials: 3 (raises risk) · Sponsor's track record
• Number of arms: 2 (raises risk) · Design
• Drug's FAERS reports before start: 61111 (lowers risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Rituximab for Idiopathic Nephrotic Syndrome NCT04494438 · started 2013 · scored riskier than 50% of active trials completed
• Efficacy and Safety of Rituximab in the First Episode of Pediatric Idiopathic Nephrotic Syndrome NCT04783675 · started 2021 · scored riskier than 54% of active trials completed
• Efficacy of Rituximab For the Treatment of Calcineurin Inhibitors Dependent Nephrotic Syndrome During Childhood NCT01268033 · started 2010 · scored riskier than 55% of active trials completed
• Compare Efficacy and Safety of Repeated Courses of Rituximab to That of Maintenance Mycophenolate Mofetil Following Single Course of Rituximab Among Children With Steroid Dependent Nephrotic Syndrome NCT03899103 · started 2019 · scored riskier than 25% of active trials completed
• Ofatumumab Versus Rituximab in Children With Steroid and Calcineurin Inhibitor Dependent Idiopathic Nephrotic Syndrome NCT02394119 · started 2015 · scored riskier than 46% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.